AnaptysBio's Second Chance to Explain What Happened Last Quarter
Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
AnaptysBio typically reports earnings before market open, meaning Day 0 captures the market's initial reaction during the first trading session, while Day +1 reflects follow-through momentum.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-05-12 | -$2.34 (-3.45%) | $5.84 (8.61%) | -$2.89 (-4.41%) | $7.25 (11.06%) |
| 2026-03-03 | -$1.39 (-3.79%) | $1.37 (3.75%) | +$5.15 (+14.61%) | $5.68 (16.12%) |
| 2025-11-04 | -$0.87 (-3.61%) | $1.27 (5.27%) | +$0.84 (+3.63%) | $3.71 (16.03%) |
| 2025-08-06 | -$0.77 (-4.85%) | $1.02 (6.48%) | -$1.45 (-9.63%) | $2.27 (15.13%) |
| 2025-05-05 | -$0.31 (-2.17%) | $0.55 (3.92%) | -$0.41 (-2.94%) | $1.05 (7.62%) |
| 2025-02-27 | -$0.40 (-3.53%) | $0.79 (7.00%) | +$0.28 (+2.56%) | $2.48 (22.68%) |
| 2024-11-05 | -$0.04 (-0.30%) | $0.62 (4.66%) | +$1.55 (+11.72%) | $1.40 (10.56%) |
| 2024-08-05 | N/A | N/A | N/A | N/A |
| Avg Abs Move | 3.10% | 5.67% | 7.07% | 14.17% |
Historical price action around earnings shows significant volatility, with an average absolute Day 0 move of 3.10% and Day +1 move of 7.07%. The most recent earnings (May 12, 2026) produced a -4.41% Day +1 decline following the massive EPS miss. However, the prior two releases demonstrated AnaptysBio's potential for explosive upside: the March 3, 2026 report generated a +14.61% Day +1 surge, while November 4, 2025 delivered a +3.63% gain.
The Day +1 range averages 14.17%, indicating substantial intraday volatility as investors digest results and reassess the company's trajectory. The pattern suggests binary outcomes—when AnaptysBio beats expectations (particularly on clinical or partnership news), the stock can rally sharply, but misses are punished severely. Given the company's recent volatility and the dramatic Q1 miss, investors should prepare for a potentially wide trading range following this release.
Part 2.2: Options Market Expected Move
| Metric | Value |
|---|---|
| Expiration Date | 09/18/26 (DTE 10) |
| Expected Move | $0.00 (0.00%) |
| Expected Range | $56.65 to $56.65 |
| Implied Volatility | 77.73% |
The options market is pricing in a 0.00% expected move for the September 18 expiration, which appears to be a data anomaly given the stock's historical earnings volatility. Based on the 7.07% average Day +1 move and 14.17% average Day +1 range from recent earnings, investors should expect significantly more movement than the options data suggests—the historical pattern indicates potential for high-single-digit to low-double-digit percentage swings.
Part 3: What Analysts Are Saying
Analyst sentiment on AnaptysBio remains overwhelmingly bullish despite recent earnings volatility. The consensus rating stands at 4.83 out of 5.00, with 11 Strong Buy ratings, 0 Moderate Buys, 1 Hold, and no Sell ratings among the 12 analysts covering the stock. This near-unanimous bullish stance reflects confidence in the company's pipeline and long-term potential, even as quarterly results remain unpredictable.
The average price target of $86.64 implies 53.1% upside from the current price of $56.60, with a range from $70.00 (23.6% upside) to $140.00 (147.3% upside). The wide target range reflects differing views on the probability and timing of clinical and commercial success, but even the most conservative target suggests meaningful appreciation potential.
Analyst sentiment has remained unchanged over the past month, indicating the recent Q1 miss has not materially altered the bullish thesis. The stability in ratings despite the -475.00% earnings surprise suggests analysts view the loss as a timing issue related to milestone payments or trial expenses rather than a fundamental deterioration in the company's prospects. The consensus appears to be looking through near-term volatility toward potential value creation from pipeline advancement and partnership opportunities.
Part 4: Technical Picture
The Barchart Technical Opinion has deteriorated sharply heading into earnings, currently showing a Sell signal at 8% compared to a Buy signal at 8% last week and a Buy signal at 56% last month. This dramatic reversal reflects weakening momentum as the stock has pulled back from recent highs.
Timeframe Analysis:
- Short-term (50% Sell): Moderate sell signal indicates near-term momentum has turned negative, suggesting caution for traders positioning ahead of the release
- Medium-term (Hold): Neutral reading suggests the intermediate trend remains in balance despite recent weakness
- Long-term (50% Buy): Moderate buy signal reflects the stock's strong performance over extended timeframes, with the price still well above longer-term averages
Trend Characteristics: The Weak strength combined with a Weakening direction suggests the technical setup is fragile heading into earnings, with momentum deteriorating but not yet decisively bearish.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $56.40 | 50-Day MA | $58.05 |
| 10-Day MA | $56.90 | 100-Day MA | $58.32 |
| 20-Day MA | $57.45 | 200-Day MA | $46.60 |
At $56.60, ANAB trades above its 5-day moving average of $56.40 but below the 10-day ($56.90), 20-day ($57.45), 50-day ($58.05), and 100-day ($58.32) averages, indicating short-term weakness within a longer-term uptrend. The stock remains well above its 200-day moving average of $46.60, confirming the broader bullish trend remains intact despite recent consolidation. The 14-day RSI of 49.27 sits in neutral territory, suggesting neither overbought nor oversold conditions. With 10-day volatility at 28.09% and the stock trading in a tight range near multiple moving averages, the technical setup is cautiously neutral—the stock lacks strong directional momentum heading into what history suggests could be a volatile earnings reaction.